Key Insights

Highlights

Treatment Research

3 treatments under study, led by Imrt

Research Leaders

5 sponsors active, led by Kaiping Central Hospital

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 4 (1)

Trial Status

Terminated1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT04850157Phase 2UnknownPrimary

Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

NCT01600196Phase 4TerminatedPrimary

Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus

Showing all 2 trials

Research Network

Common Treatments

  • Imrt1
  • Liver Resection Plus Thrombectomy1
  • Tislelizumab1

Active Sponsors

  • Kaiping Central Hospital1
  • Shanghai Zhongshan Hospital1
  • The 458 Hospital of Chinese People's Liberation Army1
  • Sun Yat-sen University1
  • Guangzhou 8th People's Hospital1

Top Investigators

Activity Timeline